The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

David Alain Wohl

The University of North Carolina at Chapel Hill

Chapel Hill

North Carolina



Name/email consistency: high



  • The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA. 2002 - 2013


  1. Raltegravir pharmacokinetics in treatment-naive patients is not influenced by race: results from the raltegravir early therapy in African-Americans living with HIV (REAL) study. Wohl, D.A., Dumond, J.B., Blevins, S., Pittard, D., Ragan, D., Wang, R., Massengale, K., Walsh, K., Floris-Moore, M., Eron, J.J., Richardson, A., Hudgens, M.G., Kashuba, A.D. Antimicrob. Agents Chemother. (2013) [Pubmed]
  2. Intensive case management before and after prison release is no more effective than comprehensive pre-release discharge planning in linking HIV-infected prisoners to care: a randomized trial. Wohl, D.A., Scheyett, A., Golin, C.E., White, B., Matuszewski, J., Bowling, M., Smith, P., Duffin, F., Rosen, D., Kaplan, A., Earp, J. AIDS. Behav (2011) [Pubmed]
  3. Low rate of CMV end-organ disease in HIV-infected patients despite low CD4+ cell counts and CMV viremia: results of ACTG protocol A5030. Wohl, D.A., Kendall, M.A., Andersen, J., Crumpacker, C., Spector, S.A., Feinberg, J., Alston-Smith, B., Owens, S., Chafey, S., Marco, M., Maxwell, S., Lurain, N., Jabs, D., Benson, C., Keiser, P., Jacobson, M.A. HIV. Clin. Trials (2009) [Pubmed]
  4. Ezetimibe alone reduces low-density lipoprotein cholesterol in HIV-infected patients receiving combination antiretroviral therapy. Wohl, D.A., Waters, D., Simpson, R.J., Richard, S., Schnell, A., Napravnik, S., Keys, J., Eron, J.J., Hsue, P. Clin. Infect. Dis. (2008) [Pubmed]
  5. Management of morphologic changes associated with antiretroviral use in HIV-infected patients. Wohl, D.A., Brown, T.T. J. Acquir. Immune Defic. Syndr. (2008) [Pubmed]
  6. Considering metabolic issues when initiating HIV therapy. Wohl, D.A. Current. Hiv/aids. Reports (2007) [Pubmed]
  7. Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Wohl, D.A., McComsey, G., Tebas, P., Brown, T.T., Glesby, M.J., Reeds, D., Shikuma, C., Mulligan, K., Dube, M., Wininger, D., Huang, J., Revuelta, M., Currier, J., Swindells, S., Fichtenbaum, C., Basar, M., Tungsiripat, M., Meyer, W., Weihe, J., Wanke, C. Clin. Infect. Dis. (2006) [Pubmed]
  8. Cytomegalovirus viremia, mortality, and end-organ disease among patients with AIDS receiving potent antiretroviral therapies. Wohl, D.A., Zeng, D., Stewart, P., Glomb, N., Alcorn, T., Jones, S., Handy, J., Fiscus, S., Weinberg, A., Gowda, D., van der Horst, C. J. Acquir. Immune Defic. Syndr. (2005) [Pubmed]
  9. Body shape, lipid, and cardiovascular complications of HIV therapy. Wohl, D.A. Current. Hiv/aids. Reports (2005) [Pubmed]
  10. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. Wohl, D.A., Kendall, M.A., Owens, S., Holland, G., Nokta, M., Spector, S.A., Schrier, R., Fiscus, S., Davis, M., Jacobson, M.A., Currier, J.S., Squires, K., Alston-Smith, B., Andersen, J., Freeman, W.R., Higgins, M., Torriani, F.J. HIV. Clin. Trials (2005) [Pubmed]
  11. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. Wohl, D.A., Tien, H.C., Busby, M., Cunningham, C., Macintosh, B., Napravnik, S., Danan, E., Donovan, K., Hossenipour, M., Simpson, R.J. Clin. Infect. Dis. (2005) [Pubmed]
  12. Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicity. Wohl, D.A., Pilcher, C.D., Evans, S., Revuelta, M., McComsey, G., Yang, Y., Zackin, R., Alston, B., Welch, S., Basar, M., Kashuba, A., Kondo, P., Martinez, A., Giardini, J., Quinn, J., Littles, M., Wingfield, H., Koletar, S.L. J. Acquir. Immune Defic. Syndr. (2004) [Pubmed]
  13. Adherence to directly observed antiretroviral therapy among human immunodeficiency virus-infected prison inmates. Wohl, D.A., Stephenson, B.L., Golin, C.E., Kiziah, C.N., Rosen, D., Ngo, B., Liu, H., Kaplan, A.H. Clin. Infect. Dis. (2003) [Pubmed]
  14. Safety, tolerability, and pharmacokinetic effects of thalidomide in patients infected with human immunodeficiency virus: AIDS Clinical Trials Group 267. Wohl, D.A., Aweeka, F.T., Schmitz, J., Pomerantz, R., Cherng, D.W., Spritzler, J., Fox, L., Simpson, D., Bell, D., Holohan, M.K., Thomas, S., Robinson, W., Kaplan, G., Teppler, H. J. Infect. Dis. (2002) [Pubmed]
WikiGenes - Universities